NEWS

In this edition:

-  DESTINY-Breast09: first-line T-DXd + pertuzumab vs. THP in HER2+ advanced/metastatic breast cancer
-  MA.40/FINER: second-line fulvestrant + ipatasertib in advanced HER2-/ER+ breast cancer
-  SERENA-6: camizestrant + CDK4/6i at emergence of ESR1 mutations with first-line aromatase inhibitor + CDK4/6i  inHR+/HER2- advanced breast cancer
-  neoCARHP: de-escalated neoadjuvant taxane, trastuzumab & pertuzumab ± carboplatin in HER2+ early breast cancer
-  Real-world outcomes of rechallenge after T-DXd-related ILD
-  OASIS 4: elinzanetant for vasomotor symptoms with adjuvant endocrine therapy
-  TEXT/SOFT: final 15-year results
-  NATALEE: efficacy of ribociclib + nonsteroidal aromatase inhibitor by age/menopausal status
-  ASCENT-04: first-line Sacituzumab govitecan + pembrolizumab in PD-L1- positive advanced TNBC
-  VERITAC-2: vepdegestrant (PROTAC ER degrader) in ER+/HER- advanced breast cancer

Read HERE